Teva Pharmaceutical Industries (TEVA) Equity Income (2017 - 2025)
Historic Equity Income for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$19.0 million.
- Teva Pharmaceutical Industries' Equity Income fell 85000.0% to -$19.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$16.5 million, marking a year-over-year decrease of 155000.0%. This contributed to the annual value of -$15.0 million for FY2025, which is 140000.0% down from last year.
- According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Equity Income is -$19.0 million, which was down 85000.0% from $2.0 million recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year Equity Income high stood at $21.0 million for Q1 2022, and its period low was -$19.0 million during Q4 2025.
- Its 5-year average for Equity Income is $647058.8, with a median of $1.0 million in 2022.
- In the last 5 years, Teva Pharmaceutical Industries' Equity Income soared by 60000.0% in 2022 and then plummeted by 90000.0% in 2024.
- Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Equity Income stood at -$5.0 million in 2021, then soared by 120.0% to $1.0 million in 2022, then tumbled by 400.0% to -$3.0 million in 2023, then soared by 33.33% to -$2.0 million in 2024, then crashed by 850.0% to -$19.0 million in 2025.
- Its last three reported values are -$19.0 million in Q4 2025, $2.0 million for Q3 2025, and $1.0 million during Q2 2025.